United States Chronic Lung Diseases Treatment Market and Forecast 2020-2026

                                          
Lung disease is a very common medical condition that is present in almost every region of the world. Chronic lung diseases can be dangerous and if not treated properly can cause death. The chronic lung diseases cause uneasiness and complications in the respiratory system thus causing difficulty in respiration.

About Bronchopulmonary Dysplasia(Facts, Figures & Treatment):
 As per an article from WHO, more than 15 million babies are born prematurely worldwide. Also, an estimated 10,000 to 15,000 newborns develop BPD in the United States every year. This correlates to about 1 in 10 births. Premature birth can lead to apnea and bronchopulmonary dysplasia, a condition that interferes with lung development and may eventually cause asthma or early onset emphysema in those born prematurely.

Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease that affects newborns. Most infants who develop BPD have been born prematurely and need oxygen therapy. Most infants recover from BPD, but some may have long-term breathing difficulties. In BPD the lungs and the airways (bronchi) are damaged, causing tissue destruction (dysplasia) in the tiny air sacs of the lung (alveoli).

In the lungs, BPD causes damage to the current and developing alveoli. Additionally, the tiny blood vessels surrounding the alveoli may be affected, making the passage of blood through the lungs more difficult. The lower the number of working alveoli, the longer the infant may need to remain on a ventilator, which can cause further damage to the child’s lungs. As the lungs of a newborn  are particularly vulnerable, high amounts of inhaled oxygen and pressure may overstretch the alveoli, causing inflammation and damage to the inside lining of the airways, the alveoli and the blood vessels around them. These effects are particularly damaging on the premature lung. BPD is considered to be primarily a complication of prematurity. Although, different conditions may affect the growth of the fetus during the pregnancy and may also lead to premature labor. Prenatal infections or maternal complications such as smoking, drug use, placental abnormalities (preeclampsia) and inflammation of the fetal membranes (chorioamnionitis) may cause BPD.

The degree of prematurity in an infant is largely what puts a child at risk of developing BPD. A majority of newborns who develop BPD are born more than 10 weeks early, weigh less than two pounds at birth, and are born with breathing problems. BPD is rare in infants born after 32 weeks of pregnancy.

In the long run, increased pressure inside the blood vessels in the lungs and between the heart and lungs can cause pulmonary hypertension. In severe cases, heart failure can occur. Newborns who suffer from BPD may also experience trouble feeding, leading to delayed development.

Caffeine is beneficial in preventing and treating apnea and bronchopulmonary dysplasia in newborns, improving the quality of life of premature infants. The caffeine citrate injection, used for apnea of the premature newborn, was initially approved by the FDA in 1999.

Market Analysis and Insights: Global Chronic Lung Diseases Treatment Market

The United States Chronic Lung Diseases Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Chronic Lung Diseases Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Chronic Lung Diseases Treatment market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Chronic Lung Diseases Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Chronic Lung Diseases Treatment market.

Chronic Lung Diseases Treatment Breakdown Data by Type

 	
Injection
 	
Capsule
 	
Tablet
 	
Other

Chronic Lung Diseases Treatment Breakdown Data by Application

 	
Bronchopulmonary Dysplasia
 	
Asthma
 	
COPD
 	
Pulmonary Fibrosi

In the competitive analysis section of the report, leading as well as prominent players of the global Chronic Lung Diseases Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.

The following players are covered in this report:

 	
Boehringer Ingelheim
 	
Novartis
 	
Roche
 	
Astellas Pharma
 	
Dr. Reddy’s Laboratories
 	
GlaxoSmithKline
 	
AstraZeneca
 	
Sanofi
 	
Teva Pharmaceuticals
 	
Asmacure Ltée'


Key Developments and Approval for Chronic Lung Disease Treatment in 2020

In August 2020,Gennisium Pharma received marketing authorization valid throughout the European Union for Gencebok which is a stimulant medicine used for treating apnoea of prematurity, a condition in which babies born prematurely stop breathing for longer than 20 seconds. Gencebok contains the active substance caffeine citrate. Gencebok is a hybrid medicine, containing the same active substance, but at a different strength. The reference medicine for Gencebok is Peyona. Apnoea in premature babies occurs because the part of the babys brain that controls breathing (breathing centre) is not fully developed. Caffeine citrate, the active substance in Gencebok, blocks the effect of adenosine. Adenosine is a natural substance that slows down the activity of some parts of the brain including the breathing centre. By reducing the effect of adenosine, caffeine citrate stimulates the brain to restore breathing. Gennisium also granted exclusive licence to Reach-Pharma for Gencebok® in Australia, New-Zealand and Papua-New Guinea. Additionally, Gennisium expanded its presence in the most important markets in Latin America, Mexico and Brazil, in granting exclusive promotion rights to Moksha8 for Gencebok®
Caffeine Citrate Injection (the generic equivalent of Hikma's, CAFCIT®), available in 60mg/3mL; has an approximate market size of $4M, annually.